Company Overview
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Why Investors Should Care
Revenue has grown at a 65.9% CAGR over the past five years.
Operating margin of 66.4% supports profitability.
Recent Developments
- Dec 2025 Revenue of $262.60M (-0.3% YoY); net profit $-80.80M.
- Trailing 12 Months Year-on-year growth — revenue +1014.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 65.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 65.94% |
| 1 Year: | 1,014.70% |
Stock Price Performance
| 1 Year: | +32.44% |
| 6 Months: | -30.96% |
| 3 Months: | +26.55% |
| 1 Month: | +8.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.58 · Neutral
P/E of 36.12 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 65.9% over 5 years.
CONS
- Trading 32.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARVN Arvinas, Inc. R2KR3KPHARMA | 9.39 | 36.12 | $613.98M | 0.00% | -20.59% | 1.59% | 65.94% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 4.00M | - | - | - | 6.20M | - | - | 5.50M | - | - | - | - | - | - | - | - | - | - | - | - | 188.80M | 22.40M | 41.90M | 9.50M | 15.60M | 249.70M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 117.40M | 93.90M | 85.70M | 84.10M | 79.40M | - |
| Operating Income | -6.32M | -6.72M | -6.41M | -5.31M | -4.28M | -8.52M | -14.06M | -16.94M | -15.81M | -18.42M | 5.50M | -22.79M | -23.41M | -26.48M | -31.75M | -41.70M | -51.90M | -47.30M | -57.70M | -65.80M | -64.30M | -87.70M | -74.60M | -73.90M | -83.30M | -48.50M | - | - | 71.40M | -71.50M | -43.80M | -74.60M | -63.80M | 164.10M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.70M | -70.10M | -42.50M | -73.40M | -62.70M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 83.10M | -61.50M | -34.80M | -67.20M | -57.50M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 200.00K | -300.00K | 300.00K | 200.00K | 100.00K | - |
| Net Income | -6.25M | -6.68M | -6.40M | -4.73M | -4.15M | -7.85M | -13.39M | -16.09M | -14.40M | -17.16M | -17.68M | -21.05M | -21.74M | -25.23M | -30.82M | -41.00M | -50.30M | -46.80M | -63.40M | -70.00M | -66.20M | -81.90M | -66.60M | -64.00M | -69.40M | -35.20M | - | - | 82.90M | -61.20M | -35.10M | -67.40M | -57.60M | 169.40M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.84 | -1.03 | -0.94 | -1.20 | -1.32 | -1.24 | -1.54 | -1.25 | -1.18 | -0.97 | -0.49 | - | - | 1.14 | -0.84 | -0.48 | -1.10 | -0.90 | 2.58 |
| R&D Expense | 7.06M | 7.82M | 7.22M | 6.69M | 7.14M | 10.34M | 13.15M | 14.56M | 14.19M | 16.00M | 16.59M | 20.41M | 21.73M | 23.42M | 30.01M | 34.90M | 43.00M | 40.60M | 64.00M | 75.30M | 77.50M | 95.30M | 103.40M | 85.90M | 84.30M | 93.70M | 86.90M | - | 90.80M | 68.60M | 64.70M | - | 60.30M | 52.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.58M | 14.30M | 18.30M | 21.80M | - | 131.40M | 78.50M | 263.40M | 262.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 394.60M | 480.00M | 513.60M | 381.10M |
| Operating Income | -24.76M | -43.80M | -51.50M | -120.80M | - | -263.20M | -401.50M | -250.20M | -118.50M |
| EBITDA | - | - | - | - | - | -255.00M | -394.80M | -243.60M | -113.30M |
| Interest Expense | - | - | - | - | 100.00K | - | - | - | - |
| Pretax Income | - | - | - | - | - | -251.00M | -363.90M | -198.30M | -80.50M |
| Tax Provision | - | - | - | - | - | 20.90M | 900.00K | 600.00K | 300.00K |
| Net Income | -24.05M | -41.48M | -70.30M | -119.30M | - | -282.50M | -367.30M | -198.90M | -80.80M |
| Diluted EPS | - | - | -2.13 | -3.02 | - | -5.31 | -6.62 | -2.77 | -1.14 |
| R&D Expense | 28.79M | 45.19M | 67.20M | 108.40M | 180.40M | 315.00M | 379.70M | 348.20M | 285.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 66.85M | 199.28M | 301.64M | 717.40M | - | 1.27B | 1.30B | 1.09B | 717.90M |
| Current Assets | - | - | - | - | - | - | 1.24B | 1.28B | 1.07B | 700.70M |
| Cash & Equivalents | - | 30.91M | 3.19M | 9.21M | 588.40M | - | 81.30M | 311.70M | 100.50M | 142.90M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 1.00M | 0 | 5.70M | 1.00M |
| Total Liabilities | - | 66.60M | 62.61M | 74.96M | 75.20M | - | 703.90M | 644.60M | 529.80M | 284.10M |
| Current Liabilities | - | 17.85M | 22.98M | 32.81M | 49.20M | - | 295.10M | 257.10M | 229.80M | 142.50M |
| Long Term Debt | - | 151.12K | 2.00M | 2.00M | 2.00M | - | 1.00M | 800.00K | 600.00K | 400.00K |
| Total Debt | - | - | - | - | - | - | 5.50M | 3.20M | 9.70M | 8.90M |
| Total Equity | -32.88M | -61.23M | 136.60M | 226.60M | 642.20M | - | 564.90M | 660.00M | 561.60M | 433.80M |
| Shares Outstanding | - | - | - | - | - | - | 53.20M | 68.00M | 68.80M | 73.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.11M | -16.12M | -40.60M | -89.70M | - | -273.50M | -347.80M | -259.30M | -273.80M |
| Investing Cash Flow | 20.87M | -179.67M | -93.10M | 164.30M | - | 242.80M | 203.50M | 34.70M | 407.60M |
| Financing Cash Flow | -161.36K | 168.06M | 139.70M | 504.60M | - | 4.70M | 374.70M | 7.90M | -91.40M |
| Capital Expenditure | -1.01M | -2.83M | -6.30M | -6.40M | - | -6.80M | -2.90M | -1.80M | -1.90M |
| Free Cash Flow | 4.10M | -18.95M | -46.90M | -96.10M | - | -280.30M | -350.70M | -261.10M | -275.70M |
| Net Change in Cash | - | - | - | - | - | -26.00M | 230.40M | -216.70M | 42.40M |
| Share Buybacks | - | - | - | - | - | - | 0 | 0 | 91.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -326.7% | -306.3% | -281.4% | -554.1% | - | -200.3% | -511.5% | -95.0% | -45.1% |
| Net Margin % | -317.3% | -290.1% | -384.2% | -547.2% | - | -215.0% | -467.9% | -75.5% | -30.8% |
| ROE % | 39.3% | -30.4% | -31.0% | -18.6% | - | -50.0% | -55.7% | -35.4% | -18.6% |
| ROCE % | -50.5% | -24.8% | -19.2% | -18.1% | - | -27.0% | -38.3% | -29.0% | -20.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 11.79% | 7.61M | $69.85M |
| 2 | Vanguard Portfolio Management LLC | 6.39% | 4.12M | $37.85M |
| 3 | Shaw D.E. & Co., Inc. | 5.42% | 3.50M | $32.09M |
| 4 | Pfizer Inc | 5.36% | 3.46M | $31.74M |
| 5 | Armistice Capital, LLC | 4.33% | 2.80M | $25.67M |
| 6 | Vanguard Capital Management LLC | 4.21% | 2.71M | $24.92M |
| 7 | Two Sigma Investments, LP | 3.99% | 2.57M | $23.62M |
| 8 | State Street Corporation | 3.40% | 2.20M | $20.17M |
| 9 | Geode Capital Management, LLC | 2.58% | 1.67M | $15.31M |
| 10 | Qube Research & Technologies Ltd | 2.47% | 1.59M | $14.62M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARVN
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPeUNRRFpZbEEzS1p3LTlLNHRGblZSMnlOUko5WGlUN0VDQ0hIajVUWFp3MFBlUkljQU9YRmh5eDhFbS1vLTRTakRiYThtRWVnODV3NkVxTEI0VXU2clB0aEp5WDhNa09odTBGaTVzSDRlcWluczRRQ21GUGpoZFZUYTRaZ1RRaGFQd0NvZ3…
Former Arvinas (NASDAQ: ARVN) officer lines up new stock sale after recent trades - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPQUl0TVItXzdnOVQ3VlRkM05nQ0pCVWx4Rm9PMDVFMktXUUZTcjdHd2tpM3F2QXRJUXJSVUZVUl9BTUhOVW5wYnBvSktOWjZQamhJX0xwOVhtYlZ0eU13Q1dZX1JId3BEMGdNZjlQTV9IbEFZUVc4YnFkNzNvWllQNzVNRkQ5S0ZPaGFtQX…
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOcFdjbW1pSWc0dzRYTldKTGdWbk4xY0V3UWtabXFnUjBfUmQ4YWdSdWxGdGphNG5lazMyN2FfRmQxR0czcTZUTzZoQUo1R29MVjNieFNpLUdLcnR1N3Z3TkFhN1lOVVNQemY3emtzY2RwNF9Vbkd6dHNNbmk1eVA5MXBnMlVjWVJPVE1jWX…
ARVN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1XNHFucXRSNGtoamZHZy1aa1lFSElPbXlDZ1d4ZTI3Q3RBYzAtUHJMUzFQeWRiZWdnVlJOdHVVdXdCekRobndyc29UVkItdWxNb2kzNHd5YnU0eHJoQkZhZ0plVHNNU19YU2FDc2lTb1JoQmlGazhnVEpn?oc=5" target="_blank">ARV…
Arvinas (ARVN) Stock Jumps As Profit Windfall Sparks Durability Debate - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOanhCMUp1cVVaTDBHekxORm5YZE83aGR5UVl1Z0xhcUhFOGFZRlZZYmp1bFZsUUs5QzJ4ZmR5aGdOeDNzOFk0M2V5ZXBXbmw3N0wtanlDQThjMURfVVVCczNBQ2hjblhfOFhGT3RJWjctWEdON0lqOTBvTi1zX1J5LXVvS0pJVFdUMjdiTk…
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish (NASDAQ:ARVN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQX2lPRTRIVlM2V3lGRG8weUluVnVMbXhMNjN5RDR0aGNEdmdzd0lFYTNCeEw3TTBGYkpNa1BEMWtuOW1iOW1xelpRdEdmMHQ1SThycEkyajBrMUJQRzVQWlc1OGMzUmRuV3hlYnRCSlZkOVBiVXVzUHphaElSMlRBUlgwTU1HXzRMNVBtTn…
ARVN — Frequently Asked Questions
What is the current share price of Arvinas, Inc. (ARVN)?
As of 2026-09-07 16:24 PDT, Arvinas, Inc. (ARVN) trades at $9.39 on NasdaqGS. Its 52-week range is $6.98 to $13.83.
What is the market capitalisation of ARVN?
Arvinas, Inc. (ARVN) has a market capitalisation of $613.98M on NasdaqGS.
What is the P/E ratio of ARVN?
ARVN trades at a trailing price-to-earnings (P/E) ratio of 36.12. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.02.
What is the return on equity (ROE) of ARVN?
ARVN has a return on equity (ROE) of 1.59%. Its return on capital employed (ROCE) is -20.59%.
Is ARVN a good stock to buy?
This page provides a data-driven analysis of Arvinas, Inc. (ARVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.